Cancer Treatment and Research

Cancer Clinical Trials: Proactive Strategies

Editors: Leong, Stanley P. L. (Ed.)

Buy this book

eBook $189.00
price for USA (gross)
  • ISBN 978-0-387-33225-3
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $249.00
price for USA
  • ISBN 978-0-387-33224-6
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
About this book

Foreword written by Samuel A. Wells, Jr., MD
Professor of Surgery
Duke University Medical Center, Durham, NC

According to the American Cancer Society, about 1 million persons in the United States will be diagnosed with solid cancer every year. About 50% of them will be potentially cured by surgery. The other half of the population may develop metastatic cancer. To date, there is no systemic treatment available to cure metastatic cancer. Therefore, cancer clinical trials are critical to evaluate reliable treatment modalities against metastatic cancer. Likewise, adjuvant trials are needed to prevent high risk patients from developing recurrence following definitive surgical resection of their cancer. Only about 3-5% of the adult cancer patients are enrolled in clinical trials. When the pediatric cancer clinical trial groups were able to accrue over 40 percent of eligible patients to their clinical trials, significant impact was made on the survival of these pediatric cancer patients. However, multiple barriers exist to block adult cancer patients from entering into clinical protocols. The ever-changing regulations for clinical trials and the ethical dilemma of treating cancer patients as subjects have made it ever so difficult for the principal investigators to conduct clinical research, especially when they are often ill-informed of the complex nature of the regulations and over-worked. Therefore, cancer clinical trials are at a critical junction. The objective of this book is to bring the issues of cancer clinical trials into focus so that proactive strategies may be developed to make such trials more user-friendly. Ultimately, the cancer patients will be benefited.

"Clinical trials remain the most important vehicle for improving the care of cancer patients. This text presents the fundamental components and challenges involving clinical investigations. Leading experts discuss the critical issues covering the spectrum of important topics from planning to application."

Steven T. Rosen, M.D.
Series Editor

Table of contents (16 chapters)

  • Historical Perspective and Evolving Concerns for Human Research

    Lo, Bernard (et al.)

    Pages 1-10

  • Cancer Trials and the Institutional Review Board (IRB)

    Kurtzman, Scott (et al.)

    Pages 11-30

  • NCI’s Cancer Therapy Evaluation Program: A Commitment to Treatment Trials

    Abrams, Jeffrey S. (et al.)

    Pages 31-50

  • The Role of the FDA in Cancer Clinical Trials

    Hirschfeld, Steven

    Pages 51-109

  • The Role of Cooperative Groups in Cancer Clinical Trials

    Mauer, Ann M. (et al.)

    Pages 111-129

Buy this book

eBook $189.00
price for USA (gross)
  • ISBN 978-0-387-33225-3
  • Digitally watermarked, DRM-free
  • Included format: PDF
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $249.00
price for USA
  • ISBN 978-0-387-33224-6
  • Free shipping for individuals worldwide
  • Usually dispatched within 3 to 5 business days.
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Cancer Clinical Trials: Proactive Strategies
Editors
  • Stanley P. L. Leong
Series Title
Cancer Treatment and Research
Series Volume
132
Copyright
2007
Publisher
Springer US
Copyright Holder
Springer-Verlag US
eBook ISBN
978-0-387-33225-3
DOI
10.1007/978-0-387-33225-3
Hardcover ISBN
978-0-387-33224-6
Series ISSN
0927-3042
Edition Number
1
Number of Pages
XX, 320
Topics